Fisher, Luminex, eGene, Sigma-Aldrich, Pfizer, Illumina, Waters, Max Planck, Sequenom | GenomeWeb
Fisher, Luminex to Develop Molecular Dx Products
 
Fisher HealthCare, a division of Thermo Fisher Scientific, and Luminex will use Luminex’s xMAP instruments and assays to jointly identify molecular diagnostic applications, Luminex said last week.  
 
Luminex, which develop and manufacture resulting products, said that by granting Fisher the US rights to its xMAP technology it gains a sales avenue through Fisher’s sales teams, its “access to key clinical accounts,” and its “extensive logistics network.”

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.